open access

Vol 13, No 2 (2019)
Review paper
Published online: 2019-06-05
Get Citation

Proton pump inhibitors in palliative care

Iwona Zaporowska-Stachowiak, Mary-Tiffany Adannia Oduah
DOI: 10.5603/PMPI.2019.0013
·
Palliat Med Pract 2019;13(2):95-100.

open access

Vol 13, No 2 (2019)
Review articles
Published online: 2019-06-05

Abstract

The gold standard treatment for peptic ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome is the class of medications known as the proton pump inhibitors (PPIs). Omeprazole, the prototype of this group belongs to the chemical class of benzimidazoles; substitution of R groups account for the variation in properties and side-effect profile of the different members of this drug class. Highly potent blocker of gastric acid secretion, this class of medications exert their effects via a dose-dependent inhibitory action on hydrogen-potassium ATPase proton pump located on the luminal side of the gastric parietal cell. Proton pump inhibitors are mostly indicated in the treatment of chemotherapy induced gastroesophageal reflux disease (GERD), in addition, they are first line agents for the treatment of dyspepsia, Helicobacter Pylori eradication, and the prevention and treatment of NSAID and glucocorticosteroid-induced ulcers. There is evidence to support the use of PPIs for treatment of hemoptysis and to limit the incidence of rebleeding palliative patients with peptic ulceration, for metastatic esophageal and gastric carcinoma. The side effect profiles vary with each drug and there is potential for drug interactions especially in the setting of polypharmacy among palliative care patients.

Abstract

The gold standard treatment for peptic ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome is the class of medications known as the proton pump inhibitors (PPIs). Omeprazole, the prototype of this group belongs to the chemical class of benzimidazoles; substitution of R groups account for the variation in properties and side-effect profile of the different members of this drug class. Highly potent blocker of gastric acid secretion, this class of medications exert their effects via a dose-dependent inhibitory action on hydrogen-potassium ATPase proton pump located on the luminal side of the gastric parietal cell. Proton pump inhibitors are mostly indicated in the treatment of chemotherapy induced gastroesophageal reflux disease (GERD), in addition, they are first line agents for the treatment of dyspepsia, Helicobacter Pylori eradication, and the prevention and treatment of NSAID and glucocorticosteroid-induced ulcers. There is evidence to support the use of PPIs for treatment of hemoptysis and to limit the incidence of rebleeding palliative patients with peptic ulceration, for metastatic esophageal and gastric carcinoma. The side effect profiles vary with each drug and there is potential for drug interactions especially in the setting of polypharmacy among palliative care patients.
Get Citation

Keywords

proton pump inhibitors (PPI), polytherapy, palliative medicine, gastroesophageal reflux disease (GERD)

About this article
Title

Proton pump inhibitors in palliative care

Journal

Palliative Medicine in Practice

Issue

Vol 13, No 2 (2019)

Article type

Review paper

Pages

95-100

Published online

2019-06-05

DOI

10.5603/PMPI.2019.0013

Bibliographic record

Palliat Med Pract 2019;13(2):95-100.

Keywords

proton pump inhibitors (PPI)
polytherapy
palliative medicine
gastroesophageal reflux disease (GERD)

Authors

Iwona Zaporowska-Stachowiak
Mary-Tiffany Adannia Oduah

References (35)
  1. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008; 10(6): 528–34.
  2. Im WB, Blakeman DP, Davis JP. Irreversible inactivation of rat gastric (H+-K+)-ATPase in vivo by omeprazole. Biochem Biophys Res Commun. 1985; 126(1): 78–82.
  3. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002; 66(2): 273–280.
  4. Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag. 2007; 3(2): 231–243.
  5. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management | Guidance and guidelines | NICE [Internet].
  6. Agar M, Webster R, Lacey J, et al. The use of subcutaneous omeprazole in the treatment of dyspepsia in palliative care patients. J Pain Symptom Manage. 2004; 28(6): 529–531.
  7. Ferguson HJ, Ferguson CI, Speakman J, et al. Management of intestinal obstruction in advanced malignancy. Ann Med Surg (Lond). 2015; 4(3): 264–270.
  8. Laval G, Marcelin-Benazech B, Guirimand F, et al. French Society for Palliative Care, French Society for Digestive Surgery, French Society for Gastroenterology, French Association for Supportive Care in Oncology, French Society for Digestive Cancer. Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manage. 2014; 48(1): 75–91.
  9. Bill Hulme and Sarah Wilcox. Guidelines on the management of bleeding for palliative care patients with cancer. Yorkshire Palliative Medicine Clinical Guidelines Group 2008.
  10. Dickman A. Drugs in Palliative Care. Oxford Medicine Online. 2012.
  11. Cheung KaS, Chan EW, Wong AYS, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for : a population-based study. Gut. 2018; 67(1): 28–35.
  12. Uwagawa T, Misawa T, Iida T, et al. Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients. J Palliat Med. 2010; 13(7): 815–818.
  13. Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017; 63(5): 354–364.
  14. Yang Yi, George KC, Shang WF, et al. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Des Devel Ther. 2017; 11: 1291–1299.
  15. Zhu J, Qi X, Yu H, et al. Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis. United European Gastroenterol J. 2018; 6(8): 1179–1187.
  16. Tsai CF, Chen MH, Wang YP, et al. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology. 2017; 152(1): 134–141.
  17. Bell EJ, St. Sauver JL, Roger VL. Proton Pump Inhibitor Use is Positively Associated with Incidence of Cardiovascular Disease. Circulation.
  18. Pello Lázaro AM, Cristóbal C, Franco-Peláez JA, et al. Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease. PLoS One. 2017; 12(1): e0169826.
  19. Xie Y, Bowe B, Li T, et al. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017; 7(6): e015735.
  20. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014; 37(4): 201–211.
  21. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010; 49(8): 509–533.
  22. Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001; 40(6): 411–426.
  23. Skrzydło-Radomańska B, Radwan P. Dexlansoprazole - a new-generation proton pump inhibitor. Przegl Gastroenterol. 2015; 10(4): 191–196.
  24. Goh KL, Choi MG, Hsu PI, et al. Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region. J Neurogastroenterol Motil. 2016; 22(3): 355–366.
  25. CPL (Polish document).
  26. Johnson DA, Katz PO, Armstrong D, et al. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs. 2017; 77(5): 547–561.
  27. Gueta I, Halkin H, Markovits N, et al. Proton pump inhibitors and the risk for gastric cancer: possible confounding by serum vitamin B . Gut. 2018; 67(10): 1904.
  28. Ramsay EN, Pratt NL, Ryan P, et al. Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs. BMC Med Res Methodol. 2013; 13: 82.
  29. Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012; 107(7): 1001–1010.
  30. Chen Y, Liu B, Glass K, et al. High incidence of hospitalisation due to infectious gastroenteritis in older people associated with poor self-rated health. BMJ Open. 2015; 5(12): e010161.
  31. Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther. 1996 ; 34(5): 185–194.
  32. Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroenterol Hepatol. 2012; 6(4): 423–435.
  33. Wang Y, Zhang H, Meng L, et al. The pharmacokinetics and bioavailability of rabeprazole following single intravenous infusion and oral administration in healthy Chinese volunteers. Drugs and Therapy Studies. 2011; 1(1): 4.
  34. Zylicz Z, van Sorge AA, Yska JP. Rectal omeprazole in the treatment of reflux pain in esophageal cancer. J Pain Symptom Manage. 1998; 15(3): 144–145.
  35. Choi MS, Chung SJ, Shim CK. Rectal absorption of omeprazole from suppository in humans. J Pharm Sci. 1996; 85(8): 893–894.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Medycyna Paliatywna w Praktyce dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl